Skip to main content
Premium Trial:

Request an Annual Quote

Sequitur Renews and Expands Functional Genomics Contract with P&G

NEW YORK, May 23 - Sequitur has extended and expanded its functional genomics collaboration with Procter & Gamble Pharmaceuticals, the company said yesterday.


The agreement, extended beyond two years, will now cover additional therapeutic areas. Sequitur, based in Natick, Mass., will continue to perform biological screening and supply its antisense/RNAi compounds and methods to P&G for use in target validation studies.


According to Sequitur, the agreement is one of its largest collaborations.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.